Alterations of ROS pathways in scleroderma begin at stem cell level.

Area of Science:

• Immunology
• Dermatology
• Cell Biology

Background:

• Scleroderma is a severe autoimmune disease causing skin fibrosis and vascular issues.
• Current scleroderma therapies are limited, highlighting the need for novel treatments.
• Oxidative stress, marked by reactive oxygen species (ROS), is crucial in scleroderma pathogenesis.

Purpose of the Study:

• To investigate the role and function of mesenchymal stem cells (MSCs) in scleroderma.
• To compare ROS production and antioxidant defenses in MSCs and fibroblasts from scleroderma patients versus healthy individuals.
• To analyze the impact of the scleroderma environment on MSCs and fibroblasts.

Main Methods:

• Isolation and characterization of MSCs and fibroblasts from scleroderma and healthy skin.
• Measurement of reactive oxygen species (ROS) production and antioxidant capacity.
• Analysis of ERK1/2 expression and response to platelet-derived growth factor (PDGF) stimulation.
• Comparison of cellular responses between MSCs and fibroblasts.

Main Results:

• Scleroderma-associated oxidative stress affects MSCs, but they retain the ability to enhance antioxidant defenses.
• Scleroderma fibroblasts exhibit impaired antioxidant mechanisms, leading to increased ROS.
• Fibroblasts show activation of pathways triggered by autoantibodies against PDGFR in scleroderma patients.

Conclusions:

• MSCs demonstrate resilience to the scleroderma pro-oxidant environment, maintaining functional antioxidant capacity.
• Scleroderma fibroblasts display a breakdown in oxidative stress management, contributing to disease progression.
• These findings suggest MSCs hold therapeutic potential for managing oxidative stress in scleroderma.